Wei Chen

Dr. Wei Chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
KLKe Li
Ke Li
QYQiandong Yao
Qiandong Yao
JXJingjing Xiao
Jingjing Xiao
MLMeng Li
Meng Li
JYJiali Yang
Jiali Yang
WCWei Chen
Wei Chen
Background: We developed a computational model integrating clinical data and imaging features extracted from contrast-enhanced computed tomography (CECT) images, to predict lymph node (LN) metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Methods: This retrospective study included 159 patients with PDAC (118 in the primary cohort and 41 in the validation cohort) who underwent preoperative contrast-enhanced computed tomography examination between 2012 and 2015. All patients underwent surgery and lymph node status was determined. A total of 2041 radiomics features were extracted from venous phase images in the primary cohort, and optimal features were extracted to construct a radiomics signature. A combined prediction model was built by incorporating the radiomics signature and clinical characteristics selected by using multivariable logistic regression. Clinical prediction models were generated and used to evaluate both cohorts. Results: Fifteen features were selected for constructing the radiomics signature based on the primary cohort. The combined prediction model for identifying preoperative lymph node metastasis reached a better discrimination power than the clinical prediction model, with an area under the curve of 0.944 vs. 0.666 in the primary cohort, and 0.912 vs. 0.713 in the validation cohort. Conclusions: This pilot study demonstrated that a noninvasive radiomics signature extracted from contrast-enhanced computed tomography imaging can be conveniently used for preoperative prediction of lymph node metastasis in patients with PDAC.

7 March 2018 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
YOYuan Ou
Yuan Ou
KCKai Chen
Kai Chen
HCHao Cai
Hao Cai
Hu ZhangHu Zhang
Hu Zhang
QGQiyong Gong
Qiyong Gong
KLKui Luo
Kui Luo
In this study, to enhance the therapeutic function and reduce the side-effects of doxorubicin (DOX), a biodegradable N-(2-hydroxypropyl) methacrylamide (HPMA) polymer–DOX conjugate has been prepared through reversible addition fragmentation chain transfer (RAFT) polymerization and conjugation chemistry, and the anticancer agent DOX was covalently linked to the polymeric vehicle through a pH-responsive hydrazone bond. The cellular mechanisms of the conjugate were explored, and the therapeutic indexes were studied as well. The high molecular weight (MW) polymeric conjugate (94 kDa) was degraded into products with low MW (45 kDa) in the presence of lysosomal cathepsin B and also showed pH-responsive drug release behavior. In vitro cellular mechanism studies revealed that the polymeric conjugate was uptaken by the 4T1 cells, leading to cell apoptosis and cytotoxicity to cancer cells, while the polymeric conjugate demonstrated excellent in vivo biosafety even at a high dose. Compared to free DOX, the conjugate has a much longer half-life in pharmacokinetics and accumulates in tumors with a much higher amount. The conjugate therefore has a much greater in vivo anticancer efficacy against 4T1 xenograft tumors and shows subtle side-effects, which were confirmed via tumor size and weight, immunohistochemistry and histological studies. Overall, this polymeric conjugate may be used as an enzyme/pH-sensitive anticancer agent.

2 July 2019 in Microchimica Acta
Verified
Journal Article
Closed access
PDF file
QHQing Huang
Qing Huang
YLYue Liu
Yue Liu
LZLinling Zheng
Linling Zheng
LWLiping Wu
Liping Wu
ZZZhengyu Zhou
Zhengyu Zhou
HZHua-Wen Zhao
Hua-Wen Zhao

15 January 2019 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
YWYou-Li Wu
You-Li Wu
FWFeng Wu
Feng Wu
CXCheng-Ping Xu
Cheng-Ping Xu
GCGuo-Lei Chen
Guo-Lei Chen
YZYu Zhang
Yu Zhang
GDGuang-Jie Duan
Guang-Jie Duan
Mediastinal follicular dendritic cell sarcoma (FDCS) is extremely rare. Due to potential under-recognization of this disease, it happens to be misdiagnosed, especially on core needle biopsy. We report 3 cases of mediastinal FDCS and provide a literature review to improve better understanding of the tumor and to reduce misdiagnosis. Three cases of mediastinal FDCS in our clinic practice were studied, including their core needle biopsy and resected specimens, and those cases reported previously in English literature were retrieved and analyzed. The core needle biopsy of case 1 showed a tumor reminiscent of classical Hodgkin’s lymphoma (CHL), while the resected mass was finally diagnosed with FDCS combined with hyaline-vascular Castleman’s disease. Both the biopsy and resected tissue of case 2 were constitutive of the clear epithelioid cells with marked atypia. In both cases, definitive diagnoses were not made on core needle biopsy. In case 3, there were some areas morphologically similar to CHL, and some areas contained ovoid to spindle-shaped tumor cells with fascicular pattern. The analysis of 43 cases of mediastinal FDCS showed the age of patients were from 16 to 76 years old, the male to female ratio was 1.5:1, the maximal tumor diameters were 3–17 cm. 18 cases were underwent preoperative biopsy, whereas 15 (83.3%) of which were misdiagnosed initially, often as lymphoma. 32 patients had available follow-up data, the rates of recurrence, metastasis, and mortality were 12.5, 18.8 and 28.1%, respectively. Current limited data suggested no statistical differences between adverse prognosis and gender, age, tumor size, necrosis, or different therapeutics, respectively. Mediastinal FDCS is a rare malignancy that has yet not been fully understood and been often misdiagnosed, particularly when making a diagnosis on core needle biopsy. Increased awareness of this enigmatic tumor is crucial to avoid diagnostic pitfalls.

4 August 2023 in European Radiology
Verified
Journal Article
Closed access
PDF file
PCPinzhen Chen
Pinzhen Chen
ZZZhou Zhou
Zhou Zhou
LSLi Sun
Li Sun
XYXueke Yu
Xueke Yu
KLKai Li
Kai Li
WCWei Chen
Wei Chen

1 January 2018
Verified
Journal Article
Closed access
XXXuanqi Xiong
Xuanqi Xiong
ZZZhengwei Zhou
Zhengwei Zhou
MFMatteo Figini
Matteo Figini
JSJunjie Shangguan
Junjie Shangguan
ZZZhuoli Zhang
Zhuoli Zhang
WCWei Chen
Wei Chen